Generic Name: lixisenatide + insulin glargine
Brand Name: Soliqua
Manufacturer: sanofi-aventis Canada Inc.
Indications: Diabetes mellitus, Type 2
Manufacturer Requested Reimbursement Criteria1:
As per indication.
Submission Type: New Combination
Project Status: Pending
Call For Patient Input: March 21, 2018
Patient Input Closed: May 10, 2018
Anticipated Date: April 19, 2018
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.